Navigation Links
BHR Pharma Engages Particle Sciences to Develop Nasal Progesterone for Traumatic Brain Injury
Date:11/19/2013

BETHLEHEM, Pa., Nov. 19, 2013 /PRNewswire/ -- Particle Sciences, a drug delivery Contract Development and Manufacturing Organization (CDMO), has been contracted by BHR Pharma to develop an in-field nasally applied formulation of Progesterone for traumatic brain injury (TBI).  BHR is pioneering this treatment and is well into their study, SyNAPSe® (Study of the Neuroprotective Activity of Progesterone in Severe Traumatic Brain Injuries), a global, Phase 3, multi-center pivotal trial in severe TBI using a parenteral formulation that was independently developed.  According to Mark Mitchnick, MD, Particle Sciences' CEO, "Particle Sciences focuses on formulation design and manufacturing.  Our clients often face challenging delivery issues so the dosage forms we work with frequently require a high level of engineering and the simplification of complex formulation challenges to commercially viable products.  In this case, the challenge was achieving rapid onset under conditions of true duress, trauma.  The product had to be versatile and durable.  BHR are world leaders in this therapeutic approach and working with their technical team we have been able to design a dosage form that meets their needs.  We look forward to helping BHR bring this very important product into the clinic and through to commercialization."        

Particle Sciences is an integrated pharmaceutical CDMO.  Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861-4701 for information.

Contact: Maureen Grieco
Maureen.Grieco@particlesciences.com


'/>"/>
SOURCE Particle Sciences
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Maximizing Production Capacity for Growth - Finding 5% for Pharmaceutical or Biotech Companies through Facility Optimization, a New Life Science Webinar from Xtalks
2. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
3. IPISC announces IP insurance for the Biotechnology/Pharma Industry
4. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
5. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
6. SignalRX Pharmaceuticals Issued U.S. Patent Covering Novel Kinase Inhibitors For Treating Cancer and Other Diseases
7. HealthEconomics.Com Distinguished Again as Top Influencer at the International Society for Pharmacoeconomics and Outcomes Research 16th Annual European Congress in Dublin
8. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
9. IPO, Earnings & Corporate Developments: Twitter, Vale SA, OCZ Technology Group, Radian Group, Keryx Biopharmaceuticals
10. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
11. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... 11, 2016 , ... Global Stem Cells Group, ... Global Stem Cells Network (GSCN) to distribute exosome injection and other biological products ... Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, Venezuela, Peru, Ecuador, ...
(Date:2/10/2016)... NX Prenatal Inc., a US based ... for early warning of adverse pregnancy outcomes, announced ... by Dr. Thomas McElrath of Brigham ... Medicine,s (SMFM) annual meeting held in ... The presentation reported initial positive top-line results regarding ...
(Date:2/10/2016)... 2016  Matchbook, Inc., a company specializing in ... companies, announced today the appointment of Jim ... brings nearly 25 years of experience in supply ... nearly two decades in executive level roles as ... Genzyme and, most recently headed global logistics and ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... Testing (PROMPT), a research registry built on the secure online PatientCrossroads platform, has ... More than 1,600 participants have joined the PROMPT study, which seeks to advance ...
Breaking Biology Technology:
(Date:2/4/2016)... 2016 The field of Human Microbiome ... most popular hubs of the biotechnology industry. While ... studies of human microbiota, have garnered a lot ... microbiome space has literally exploded in terms of ... report focuses on biomedical aspects of research, development, ...
(Date:2/3/2016)... India , February 3, 2016 ... the new market research report "Automated Fingerprint Identification System ... Search, Latent Search), Application (Banking & Finance, Government, Healthcare, ... published by MarketsandMarkets, the market is expected to be ... CAGR of 21.0% between 2015 and 2020. The transformation ...
(Date:2/3/2016)... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) ... "Emotion Detection and Recognition Market by Technology ... Tools (Facial Expression, Voice Recognition and Others), ... Global forecast to 2020" report to ... ) has announced the addition of the ...
Breaking Biology News(10 mins):